Filing Flows › Alkermes (ALKS) › Q3 2026
Alkermes (ALKS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Alkermes (ALKS) reported revenue of $480M for the third quarter 2026 (Q3 2026), +22% from a year earlier and -3% from the quarter before. Operating margin was 7.5%, net earnings $16.3M (3.4% of revenue).
Alkermes, Q3 2026: revenue $480M (+22% year over year), operating margin 7.5%, net earnings $16.3M, operating cash flow $93.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $480M | -3% | +22% |
| Operating profit | $36.0M | +96% | -60% |
| Net earnings | $16.3M | 33× | -80% |
| Operating cash flow | $93.5M | -36% | -8% |
| Free cash flow | $90.1M | -34% | +7% |
What changed
Revenue was $480.1M in Q3 2026, up 22% year over year and down 3% from the previous quarter. Vivitrol was the largest line at 27% of revenue. Vivitrol added $6.4M year over year (up 5%), 7% of the total change. Royalty declined 7%.
Operating profit was $36.0M, a 7.5% margin (down 15.1 points year over year). Operating profit fell $53.1M even though revenue rose $85.9M versus Q3 2025, so costs grew faster than sales. Total costs grew 46% against revenue growth of 22%. The fastest-growing cost line was Cost of revenue (+83%). Net earnings were $16.3M, down 80% year over year. The effective tax rate was -10.5%.
Operating cash flow was $93.5M (down 8% year over year), 574% of net earnings. Non-cash charges added back $27.2M of depreciation and amortization and $26.7M of share-based compensation. Working capital and other items added $23.3M. Capital expenditures of $3.4M left free cash flow of $90.1M.
Questions
What was Alkermes' revenue in the third quarter 2026?
Alkermes (ALKS) reported revenue of $480M for the third quarter 2026 (Q3 2026), +22% from a year earlier and -3% from the quarter before.
Was Alkermes profitable in the third quarter 2026?
Operating profit was $36.0M (7.5% of revenue) and net earnings $16.3M.
Source: Alkermes 10-Q on SEC EDGAR.